Indian businesses are struggling under GST 2.0, with an inverted duty structure hitting FMCG and OTC pharma firms hard. Experts point to the phase-out of the GST compensation cess, which has left companies with a backlog of unusable credits. On top of this, tighter free-trade agreement rules are creating fresh compliance and trade barriers.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
